ZYME on Nasdaq
Zymeworks
Logo: Unknown author Unknown author, CC BY-SA 4.0, via Wikimedia Commons4
Canadian biotechnology company
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 18, 2026.
Overview
2003Founded1
Compare with ZEVRA THERAPEUTICS, INC., Theravance Biopharma, Inc. or ImmunoGen Inc., or pick any stock.
- TickerZYME on Nasdaq1
- Industrypharmaceutical industry1
- HeadquartersVancouver1
- Websitewww.zymeworks.com
- Legal formDelaware corporation1
See how the biggest companies compare on our leaderboards
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-87.3%Operating margin5
-76.6%Net margin5
38.9%Revenue growth, 20255
-30.2%Return on equity5
-$34.5MFree cash flow5
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Other costs99¢$104.6M
- Income tax1¢$1.4M
Out of $106.0M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development collaborations (note 11) | $106.0M | $76.3M | $76.0M |
| Research and development | $137.0M | $134.6M | $143.6M |
| General and administrative | $61.5M | $61.5M | $70.4M |
| Impairment on IPR&D (note 6) | $0 | $17.3M | $0 |
| Total operating expenses | $198.5M | $213.4M | $214.1M |
| Loss from operations | -$92.5M | -$137.1M | -$138.1M |
| Interest income | $13.4M | $19.9M | $19.7M |
| Other (expense) income, net (note 12) | -$559.0K | $558.0K | -$894.0K |
| Total other income, net | $12.8M | $20.5M | $18.8M |
| Loss before income taxes | -$79.8M | -$116.6M | -$119.2M |
| Income tax (expense) recovery (note 13) | -$1.4M | -$6.1M | $568.0K |
| Net loss | -$81.1M | -$122.7M | -$118.7M |
| Unrealized income (loss) on available for sale securities, net of tax of nil (note 5) | $873.0K | -$349.0K | $56.0K |
| Total other comprehensive income (loss) | $873.0K | -$349.0K | $56.0K |
| Comprehensive loss | -$80.3M | -$123.0M | -$118.6M |
| Basic (in dollars per share) | -$1.08 | -$1.62 | -$1.72 |
| Diluted (in dollars per share) | -$1.08 | -$1.62 | -$1.72 |
| Basic (in shares) | 75.4M shares | 75.8M shares | 68.9M shares |
| Diluted (in shares) | 75.4M shares | 75.9M shares | 68.9M shares |
| Unrealized loss on available for sale securities, tax | $0 | $0 | $0 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2025-11-30 | 2024-12-31 | 2024-07-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $41.2M | $66.1M | |||
| Short-term marketable securities (note 5) | $187.6M | $159.7M | |||
| Accounts receivable | $4.6M | $55.8M | |||
| Prepaid expenses and other current assets | $15.3M | $18.9M | |||
| Total current assets | $248.8M | $300.5M | |||
| Long-term marketable securities (note 5) | $41.8M | $98.4M | |||
| Long-term prepaids and other assets | $6.7M | $8.9M | |||
| Deferred tax asset (note 13) | $4.7M | $4.4M | |||
| Property and equipment, net (note 7) | $15.5M | $17.6M | |||
| Operating lease right-of-use assets (note 14) | $15.7M | $16.7M | |||
| Intangible assets, net (note 8) | $1.4M | $4.6M | |||
| Goodwill (note 6) | $12.0M | $12.0M | |||
| Total assets | $346.5M | $463.1M | |||
| Accounts payable and accrued liabilities (note 9) | $36.3M | $59.8M | |||
| Income tax payable (note 13) | $83.0K | $128.0K | |||
| Current portion of operating lease liability (note 14) | $3.5M | $2.7M | |||
| Deferred revenue and other consideration (note 11) | $2.4M | $25.6M | |||
| Total current liabilities | $42.3M | $88.3M | |||
| Long-term portion of operating lease liability (note 14) | $14.8M | $15.7M | |||
| Deferred revenue (note 11) | $14.6M | $14.6M | |||
| Other long-term liabilities (note 9) | $278.0K | $923.0K | |||
| Deferred tax liability (note 13) | $6.0M | $4.8M | |||
| Total liabilities | $78.0M | $124.3M | |||
| Common shares, $0.00001 par value; 900,000,000 authorized shares of common stock at December 31, 2025 and December 31, 2024 (74,638,413 and 68,964,319 shares issued and outstanding at December 31, 2025 and 2024, respectively (note 10b). | $1.1B | $1.0B | |||
| Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of December 31, 2025 and December 31, 2024 (note 10b). | $0 | $0 | |||
| Exchangeable shares, no par value, 553,184 issued and outstanding shares at December 31, 2025 (December 31, 2024: 570,637) (note 10b). | $7.9M | $8.2M | |||
| Additional paid-in capital | $114.6M | $152.2M | |||
| Accumulated other comprehensive loss | -$6.1M | -$7.0M | |||
| Accumulated deficit | -$953.2M | -$830.3M | |||
| Total stockholders equity | $268.5M | $338.8M | $464.8M | ||
| Total liabilities and stockholders equity | $346.5M | $463.1M | |||
| Common stock, par value per share (in dollars per share) | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 900.0M shares | 900.0M shares | |||
| Common shares, issued (in shares) | 74.6M shares | 69.0M shares | |||
| Common shares, outstanding (in shares) | 74.6M shares | 69.0M shares | |||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |||
| Preferred stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | |||
| Preferred stock, shares issued (in shares) | 1 shares | 1 shares | |||
| Preferred stock, shares outstanding (in shares) | 1 shares | 1 shares | |||
| Exchangeable stock, shares issued (in shares) | 553.2K shares | 570.6K shares | |||
| Exchangeable shares, shares outstanding (in shares) | 553.2K shares | 570.6K shares |
| Period ending | 2025-12-31 | 2025-11-30 | 2024-12-31 | 2024-07-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | $41.2M | $66.1M | ||||
| Short-term marketable securities (note 5) | $187.6M | $159.7M | ||||
| Accounts receivable | $4.6M | $55.8M | ||||
| Prepaid expenses and other current assets | $15.3M | $18.9M | ||||
| Total current assets | $248.8M | $300.5M | ||||
| Long-term marketable securities (note 5) | $41.8M | $98.4M | ||||
| Long-term prepaids and other assets | $6.7M | $8.9M | ||||
| Deferred tax asset (note 13) | $4.7M | $4.4M | ||||
| Property and equipment, net (note 7) | $15.5M | $17.6M | ||||
| Operating lease right-of-use assets (note 14) | $15.7M | $16.7M | ||||
| Intangible assets, net (note 8) | $1.4M | $4.6M | ||||
| Goodwill (note 6) | $12.0M | $12.0M | ||||
| Total assets | $346.5M | $463.1M | ||||
| Accounts payable and accrued liabilities (note 9) | $36.3M | $59.8M | ||||
| Income tax payable (note 13) | $83.0K | $128.0K | ||||
| Current portion of operating lease liability (note 14) | $3.5M | $2.7M | ||||
| Deferred revenue and other consideration (note 11) | $2.4M | $25.6M | ||||
| Total current liabilities | $42.3M | $88.3M | ||||
| Long-term portion of operating lease liability (note 14) | $14.8M | $15.7M | ||||
| Deferred revenue (note 11) | $14.6M | $14.6M | ||||
| Other long-term liabilities (note 9) | $278.0K | $923.0K | ||||
| Deferred tax liability (note 13) | $6.0M | $4.8M | ||||
| Total liabilities | $78.0M | $124.3M | ||||
| Common shares, $0.00001 par value; 900,000,000 authorized shares of common stock at December 31, 2025 and December 31, 2024 (74,638,413 and 68,964,319 shares issued and outstanding at December 31, 2025 and 2024, respectively (note 10b). | $1.1B | $1.0B | ||||
| Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of December 31, 2025 and December 31, 2024 (note 10b). | $0 | $0 | ||||
| Exchangeable shares, no par value, 553,184 issued and outstanding shares at December 31, 2025 (December 31, 2024: 570,637) (note 10b). | $7.9M | $8.2M | ||||
| Additional paid-in capital | $114.6M | $152.2M | ||||
| Accumulated other comprehensive loss | -$6.1M | -$7.0M | ||||
| Accumulated deficit | -$953.2M | -$830.3M | ||||
| Total stockholders equity | $268.5M | $338.8M | $464.8M | $493.0M | ||
| Total liabilities and stockholders equity | $346.5M | $463.1M | ||||
| Common stock, par value per share (in dollars per share) | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 900.0M shares | 900.0M shares | ||||
| Common shares, issued (in shares) | 74.6M shares | 69.0M shares | ||||
| Common shares, outstanding (in shares) | 74.6M shares | 69.0M shares | ||||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||||
| Preferred stock, shares authorized (in shares) | 100.0M shares | 100.0M shares | ||||
| Preferred stock, shares issued (in shares) | 1 shares | 1 shares | ||||
| Preferred stock, shares outstanding (in shares) | 1 shares | 1 shares | ||||
| Exchangeable stock, shares issued (in shares) | 553.2K shares | 570.6K shares | ||||
| Exchangeable shares, shares outstanding (in shares) | 553.2K shares | 570.6K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$81.1M | -$122.7M | -$118.7M |
| Depreciation of property and equipment (note 7) | $3.7M | $4.2M | $7.5M |
| Amortization of intangible assets (note 8) | $4.1M | $4.5M | $2.7M |
| Stock-based compensation (note 10e) | $28.0M | $17.8M | $8.1M |
| Amortization and impairment of operating lease right-of-use assets | $3.4M | $2.5M | $7.1M |
| Impairment of acquired IPR&D (note 6) | $0 | $17.3M | $0 |
| Deferred income tax expense (recovery) (note 13) | $945.0K | $691.0K | -$757.0K |
| Change in fair value of contingent consideration liability (note 15) | $0 | -$1.9M | $630.0K |
| Change in fair value of investments in equity instruments | $0 | $0 | $667.0K |
| Unrealized foreign exchange loss (gain) | $532.0K | -$1.5M | -$31.0K |
| Accounts receivable | $51.2M | -$36.4M | $13.9M |
| Prepaid expenses and other current assets | $6.5M | -$2.5M | $4.3M |
| Accounts payable and accrued liabilities | -$23.6M | $14.3M | -$44.8M |
| Operating lease liabilities | -$3.3M | -$8.3M | -$3.7M |
| Deferred revenue and other consideration | -$23.2M | $3.6M | $3.7M |
| Income taxes payable | -$45.0K | -$1.7M | $970.0K |
| Net cash used in operating activities | -$33.0M | -$110.1M | -$118.3M |
| Proceeds from issuance of common stock under at-the-market program and from public offerings, net of issuance costs (notes 10a) | $0 | $0 | $26.2M |
| Private placement (note 10a) | $5.0M | $0 | $49.9M |
| Issuance of common stock on exercise of stock options (note 10e) | $16.9M | $8.9M | $5.0M |
| Issuance of common stock through employee stock purchase plan (note 10f) | $1.4M | $930.0K | $820.0K |
| Purchases of common stock for retirement (note 10c) | -$41.7M | -$30.1M | $0 |
| Deferred financing fees | -$181.0K | -$174.0K | -$53.0K |
| Net cash (used in) / provided by financing activities | -$18.6M | -$20.4M | $81.9M |
| Purchases of marketable securities | -$196.1M | -$283.7M | -$553.2M |
| Proceeds from marketable securities | $225.1M | $325.6M | $350.1M |
| Acquisition of property and equipment | -$1.5M | -$2.0M | -$2.5M |
| Acquisition of intangible assets | -$831.0K | -$1.1M | -$1.6M |
| Net cash provided by / (used in) investing activities | $26.7M | $38.8M | -$207.3M |
| Effect of exchange rate changes on cash and cash equivalents | -$45.0K | $286.0K | $354.0K |
| Net change in cash and cash equivalents | -$24.9M | -$91.5M | -$243.4M |
| Net cash paid during the year for income taxes | $1.4M | $3.2M | $165.0K |
| Leased assets obtained in exchange for operating lease liabilities | $2.4M | $644.0K | $1.9M |
| Issuance of common stock upon exercise of pre-funded warrants (note 10d) | $49.9M | $0 | $0 |
| Purchases of common stock not settled | $464.0K | $0 | $0 |
| Acquisition of property and equipment and intangible assets in accounts payable and accrued liabilities | $0 | $0 | $122.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Zymeworks, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
20052010201520202025
- Chief executive officerKenneth Galbraith Jan 18, 2022 to Jan 18, 202213
- Chief executive officerKenneth Galbraith Dec 23, 2022 to now14
- Chief executive officerAli Tehrani Jan 2, 2019 to Jul 16, 202115
- ChairKenneth Galbraith Jan 18, 2022 to Jan 18, 202213
- ChairKenneth Galbraith Dec 23, 2022 to now14
- PresidentNeil A. Klompas Jan 6, 2023 to Mar 14, 202316
- PresidentKenneth Galbraith Jan 18, 2022 to Jan 18, 202213
- Chief financial officerChristopher Astle Mar 4, 2022 to Mar 11, 202217
- Chief financial officerChristopher Astle Dec 14, 2022 to Jan 8, 202418
- Chief financial officerNeil A. Klompas Jan 2, 2019 to Jan 7, 202219
- Chief operating officerMark Hollywood Jan 13, 2026 to now20
- Chief operating officerNeil A. Klompas Jan 6, 2023 to Mar 14, 202316
- Chief operating officerNeil A. Klompas Jan 7, 2022 to Jul 5, 202221
Board members and other officers (41)
- SVP & Chief Medical OfficerSabeen Mekan Feb 2, 2026 to now22
- OfficerAdam Schayowitz Apr 10, 2026 to now23
- EVP, Chief Business OfficerScott Platshon Apr 10, 2026 to now24
- EVP, Chief Bus & Fin OfficerLeone D. Patterson Sep 3, 2024 to now25
- Chief Scientific OfficerPaul Andrew Moore Jan 6, 2023 to now26
- Chief Scientific OfficerPaul Andrew Moore Jul 19, 2022 to Jul 19, 202227
- Chief Medical OfficerNeil Josephson Nov 14, 2022 to Dec 23, 202228
- Chief Commercial OfficerJames Priour Feb 3, 2021 to Jul 8, 202129
- Interim Chief Medical OfficerNeil Josephson May 25, 2021 to Nov 14, 202230
- Chief Scientific OfficerAnthony J. Polverino Jan 2, 2019 to Jan 7, 202231
- OfficerDavid Kai Yuen Poon Jan 2, 2019 to May 8, 201932
- Chief Medical OfficerDiana Hausman Jan 2, 2019 to Mar 12, 202133
- Chief People OfficerKathryn O'Driscoll Oct 22, 2019 to Jul 8, 202134
- Board memberBrian N. Cherry Jan 13, 2026 to now35
- Board memberOleg Nodelman Feb 18, 2025 to now36
- Board memberGregory Austin Ciongoli Aug 12, 2025 to now37
- Board memberRobert E. Landry Aug 12, 2025 to now38
- Board memberAlessandra Cesano Feb 9, 2024 to now39
- Board memberScott Platshon Mar 4, 2024 to Mar 4, 202440
- Board memberNeil Gallagher Apr 2, 2024 to Dec 12, 202441
- Board memberCarlos Campoy Jun 30, 2023 to now42
- Board memberNancy Davidson Dec 8, 2023 to Dec 12, 202443
- Board memberHollings Renton Dec 23, 2022 to Dec 8, 202344
- Board memberKelvin Neu Dec 23, 2022 to now45
- Board memberKenneth Hillan Dec 23, 2022 to Dec 8, 202346
- Board memberLota S. Zoth Dec 23, 2022 to Dec 23, 202247
- Board memberNatalie Sacks Dec 23, 2022 to Dec 23, 202248
- Board memberSusan Mahony Dec 23, 2022 to now49
- Board memberTroy Cox Dec 23, 2022 to Dec 12, 202450
- Board memberFelix Baker Mar 16, 2020 to May 12, 202051
- Board memberJulian Baker Mar 16, 2020 to May 12, 202051
- Board memberKelvin Neu Mar 16, 2020 to May 7, 202152
- Board memberL.p. 667 Mar 16, 2020 to May 12, 202051
- Board memberAli Tehrani Jan 2, 2019 to Jul 16, 202115
- Board memberHollings Renton Jan 2, 2019 to May 7, 202153
- Board memberKenneth Hillan Jan 2, 2019 to May 7, 202154
- Board memberLota S. Zoth Jan 2, 2019 to May 7, 202155
- Board memberNatalie Sacks Jan 2, 2019 to May 7, 202156
- Board memberNick Bedford Jan 2, 2019 to May 8, 201957
- Board memberSusan Mahony Jun 11, 2019 to May 7, 202158
- Board memberTroy Cox Jun 11, 2019 to May 7, 202159
Products and brands
- medication
Listed on Wikidata.1
Timeline
Filings
450 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 138 major events, 135 insider forms, 55 large holders, 1 private raises, 99 other. The latest 20:
- Oct 9, 20264 EDGAR
- Oct 9, 2026144 EDGAR
- Sep 23, 20268-K EDGAR
- Aug 25, 20268-K EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 6, 20264 EDGAR
- Jun 29, 20268-K EDGAR
- May 15, 20264 EDGAR
- May 15, 20263 EDGAR
- May 15, 2026SCHEDULE 13G/A EDGAR
- May 14, 20268-K EDGAR
- May 7, 202610-Q EDGAR
- May 7, 20268-K EDGAR
- Apr 15, 2026SCHEDULE 13G EDGAR
- Apr 10, 20264 EDGAR
- Apr 10, 20264 EDGAR
- Apr 10, 20263 EDGAR
- Apr 10, 20263 EDGAR
- Apr 7, 20264 EDGAR
The 450 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 55 such filings since October 2021, the latest 10:
- May 15, 2026SCHEDULE 13G/A
- Apr 15, 2026SCHEDULE 13G
- Feb 13, 2026SCHEDULE 13G/A
- Feb 12, 2026SCHEDULE 13G/A
- Nov 19, 2025SCHEDULE 13D/A
- Nov 14, 2025SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
- Jun 27, 2025SCHEDULE 13D
- May 7, 2025SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Dec 28, 2023Raised $50 million in a private offering of equity Form D: $50 million offered in all Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 22,970,388 | $600.4M | 29.8% | No change |
| Rubric Capital Management LP | 7,000,000 | $183.0M | 1.7% | No change |
| BlackRock, Inc. | 4,251,030 | $111.1M | 0.0% | −302,858 |
| Perceptive Advisors LLC | 4,182,953 | $109.3M | 1.7% | +672,875 |
| Bvf Inc/il | 3,649,142 | $95.4M | 2.4% | −85,000 |
| Assenagon Asset Management S.A. | 2,504,054 | $65.5M | 0.0% | +1,776,068 |
| Morgan Stanley | 2,231,260 | $58.3M | 0.0% | −249,308 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,781,116 | $46.6M | 0.0% | −126,923 |
| Vanguard Capital Management LLC | 1,558,998 | $40.8M | 0.0% | −146,582 |
| Nextech Invest Ltd. | 1,113,946 | $29.1M | 1.4% | No change |
| State Street Corp | 1,088,216 | $28.4M | 0.0% | +76,439 |
| Dimensional Fund Advisors LP | 994,955 | $26.0M | 0.0% | −144,180 |
| Citadel Advisors LLC | 914,136 | $23.9M | 0.0% | −235,882 |
| Nomura Asset Management International Inc. | 889,802 | $23.3M | 0.0% | New |
| Fmr LLC | 702,568 | $18.4M | 0.0% | +35,415 |
| Geode Capital Management, LLC | 692,410 | $18.1M | 0.0% | +32,470 |
| Prosight Management, LP | 674,434 | $17.6M | 3.0% | +135,385 |
| Qube Research & Technologies Ltd | 593,590 | $15.5M | 0.0% | +81,653 |
| Vanguard Portfolio Management LLC | 510,032 | $13.3M | 0.0% | +10,157 |
| Redmile Group, LLC | 491,654 | $12.9M | 0.9% | No change |
| Capricorn Fund Managers Ltd | 486,529 | $12.7M | 1.0% | −520,681 |
| Goldman Sachs Group Inc | 470,822 | $12.3M | 0.0% | −128,664 |
| Arrowstreet Capital, Limited Partnership | 418,497 | $10.9M | 0.0% | −325,401 |
| Deutsche Bank Ag\ | 397,190 | $10.4M | 0.0% | −524,060 |
| Hillsdale Investment Management Inc. | 382,922 | $10.0M | 0.2% | +37,300 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.zymeworks.com1
- X (Twitter)x.com/ZymeworksInc1
- WikipediaZymeworks
- WikidataQ16968498
- SEC EDGARCIK 1403752
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataZymeworks on Wikidata
- 2SEC EDGARZymeworks filings on SEC EDGAR
- 3WikipediaZymeworks on Wikipedia
- 4Wikimedia CommonsZymeworks logo by Unknown author Unknown author, CC BY-SA 4.0
- 5SEC EDGARZymeworks 10-K for fiscal 2025
- 6SEC EDGARZymeworks 10-K for fiscal 2019
- 7SEC EDGARZymeworks 10-K for fiscal 2020
- 8SEC EDGARZymeworks 10-K for fiscal 2021
- 9SEC EDGARZymeworks 10-K for fiscal 2022
- 10SEC EDGARZymeworks 10-Q for fiscal 2026
- 11SEC EDGARZymeworks 10-Q for fiscal 2026
- 12SEC EDGARZymeworks 10-K for fiscal 2019
- 13
- 14
- 15SEC EDGARAli Tehrani, Chief executive officer
- 16SEC EDGARNeil A. Klompas, President
- 17
- 18
- 19
- 20
- 21
- 22
- 23SEC EDGARAdam Schayowitz, Officer
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32SEC EDGARDavid Kai Yuen Poon, Officer
- 33SEC EDGARDiana Hausman, Chief Medical Officer
- 34
- 35SEC EDGARBrian N. Cherry, Board member
- 36SEC EDGAROleg Nodelman, Board member
- 37
- 38SEC EDGARRobert E. Landry, Board member
- 39SEC EDGARAlessandra Cesano, Board member
- 40SEC EDGARScott Platshon, Board member
- 41SEC EDGARNeil Gallagher, Board member
- 42SEC EDGARCarlos Campoy, Board member
- 43SEC EDGARNancy Davidson, Board member
- 44SEC EDGARHollings Renton, Board member
- 45SEC EDGARKelvin Neu, Board member
- 46SEC EDGARKenneth Hillan, Board member
- 47SEC EDGARLota S. Zoth, Board member
- 48SEC EDGARNatalie Sacks, Board member
- 49SEC EDGARSusan Mahony, Board member
- 50SEC EDGARTroy Cox, Board member
- 51SEC EDGARFelix Baker, Board member
- 52SEC EDGARKelvin Neu, Board member
- 53SEC EDGARHollings Renton, Board member
- 54SEC EDGARKenneth Hillan, Board member
- 55SEC EDGARLota S. Zoth, Board member
- 56SEC EDGARNatalie Sacks, Board member
- 57SEC EDGARNick Bedford, Board member
- 58SEC EDGARSusan Mahony, Board member
- 59SEC EDGARTroy Cox, Board member